This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Lazzarotto D, Candoni A, Filì C, Forghieri F, Pagano L, Busca A, et al. Clinical outcome of myeloid sarcoma in adult patients and effect of allogeneic stem cell transplantation. Results from a multicenter survey. Leuk Res. 2017;53:74–81.
Bakst RL, Tallman MS, Douer D, Yahalom J. How I treat extramedullary acute myeloid leukemia. Blood. 2011;118:3785–93.
Shimizu H, Saitoh T, Tanaka M, Mori T, Sakura T, Kawai N, et al. Allogeneic hematopoietic stem cell transplantation for adult AML patients with granulocytic sarcoma. Leukemia. 2012;26:2469–73.
Goyal SD, Zhang MJ, Wang HL, Akpek G, Copelan EA, Freytes C, et al. Allogeneic hematopoietic cell transplant for AML: no impact of pre-transplant extramedullary disease on outcome. Bone Marrow Transpl. 2015;50:1057–62.
Aoki J, Ishiyama K, Taniguchi S, Fukuda T, Ohashi K, Ogawa H, et al. Outcome of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with central nervous system involvement. Biol Blood Marrow Transpl. 2014;20:2029–33.
Bar M, Tong W, Othus M, Loeb KR, Estey EH. Central nervous system involvement in acute myeloid leukemia patients undergoing hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2015;21:546–51.
Atsuta Y, Suzuki R, Yoshimi A, Gondo H, Tanaka J, Hiraoka A, et al. Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP system. Int J Hematol. 2007;86:269–74.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Acute Myeloid Leukemia (Version 2.2018). https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf. Accessed 20 Oct 2018.
Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transpl. 2013;48:452–8.
Gunes G, Goker H, Demiroglu H, Malkan UY, Buyukasik Y. Extramedullary relapses of acute leukemias after allogeneic hematopoietic stem cell transplantation: clinical features, cumulative incidence, and risk factors. Bone Marrow Transpl. 2019;54:595–600.
Yamasaki S, Yoshimoto G, Ogawa R, Aoki K, Higuchi M, Harada N, et al. Factors prognostic of eligibility for allogeneic HCT among older patients with AML-CR1 and adverse- or intermediate-risk cytogenetics. Ann Hematol. 2015;94:1159–65.
Yamasaki S, Hirakawa A, Aoki J, Uchida N, Fukuda T, Ogawa H, et al. Role of reduced-intensity conditioning allogeneic hematopoietic cell transplantation in older patients with de novo acute myeloid leukemia. Ann Hematol. 2017;96:289–97.
Acknowledgements
We appreciate the patients and clinical staff for their participation in the study. We are very grateful to the Japanese Data Center for Hematopoietic Cell Transplantation for data management and the Clinical Research Institute of Kyushu Medical Hospital for their editorial support. This study was supported by The Practical Research Project for Allergic Diseases and Immunology (Research Technology of Medical Transplantation) of the Japan Agency for Medical Research and Development (AMED). We thank Edanz Group (www.edanzediting.com) for editing a draft of this manuscript.
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
This study was approved by the Data Management Committee of the Japanese Society for Hematopoietic Cell Transplantation and the Institutional Review Board of Kyushu Medical Center. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Additional information
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Yamasaki, S., Aoki, J., Mori, J. et al. Better disease control before allogeneic stem cell transplantation is crucial to improve the outcomes of transplantation for acute myeloid leukemia patients with extramedullary disease. Bone Marrow Transplant 55, 249–252 (2020). https://doi.org/10.1038/s41409-019-0527-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-019-0527-z
This article is cited by
-
Pretransplant hepatomegaly is linked to relapse in patients with leukemia and myelodysplastic syndrome not in remission
International Journal of Hematology (2024)
-
Effect of extramedullary disease on allogeneic hematopoietic cell transplantation for pediatric acute myeloid leukemia: a nationwide retrospective study
Bone Marrow Transplantation (2021)
-
Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia conducted in Japan during the past quarter century
Annals of Hematology (2020)
-
Pathogen-Specific T Cells Beyond CMV, EBV and Adenovirus
Current Hematologic Malignancy Reports (2019)